Longeveron (LGVN) Expected to Post Quarterly Earnings on Wednesday

Longeveron (NASDAQ:LGVN) is expected to issue its Q2 2026 results after the market closes on Wednesday, August 12th. Analysts expect Longeveron to post earnings of ($0.19) per share and revenue of $0.3260 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:30 PM ET.

Longeveron (NASDAQ:LGVN) last announced its earnings results on Wednesday, May 13th. The company reported ($0.19) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.19). Longeveron had a negative net margin of 1,844.49% and a negative return on equity of 202.41%. The business had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.33 million. On average, analysts expect Longeveron to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Longeveron Stock Performance

Shares of Longeveron stock opened at $0.75 on Wednesday. The business has a 50-day moving average price of $0.71 and a two-hundred day moving average price of $0.75. Longeveron has a 1-year low of $0.47 and a 1-year high of $1.58. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.05. The company has a market cap of $23.42 million, a P/E ratio of -0.67 and a beta of -0.31.

Institutional Investors Weigh In On Longeveron

An institutional investor recently bought a new position in Longeveron stock. XTX Topco Ltd bought a new stake in Longeveron Inc. (NASDAQ:LGVN) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned approximately 0.32% of Longeveron as of its most recent SEC filing. Institutional investors own 10.01% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on LGVN. HC Wainwright decreased their target price on Longeveron from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, May 4th. Maxim Group lowered shares of Longeveron from a “buy” rating to a “hold” rating in a research note on Monday, May 11th. Weiss Ratings raised shares of Longeveron from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 28th. Finally, Wall Street Zen downgraded shares of Longeveron from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $5.50.

Longeveron Company Profile

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.